Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 26, 2025Annals of HematologyOpen Access

Infectious complications in CLL/SLL patients receiving Bruton's Tyrosine Kinase inhibitors – systematic review and meta-analysis of randomized controlled trials

View Full Paper
Ask AI
Bookmark
Share

Authors

SBShira BuchritsGTGal TriemanOGOdil Giladi

Discussion

Loading...

Member takes

Overview

Systematic review finds no overall infection risk increase with BTK inhibitors in CLL/SLL, highlighting pneumonia concerns.

Key Points

  • Bruton's tyrosine kinase inhibitors showed no significant increase in overall infections in CLL/SLL patients.
  • Eighteen randomized controlled trials with 8,324 patients assessed the risk of infections with BTK inhibitors.
  • Pneumonia risk was notably higher with BTK plus anti-CD20 compared to other regimens, with RR 2.18.
  • BTK inhibitors reduced the risk of febrile neutropenia, suggesting a potential advantage in treatment regimens.

Cite This Study

Buchrits et al. (2025) studied this question.

synapsesocial.com/papers/689a0933e6551bb0af8ce573https://doi.org/10.1007/s00277-025-06502-y
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Risk of Invasive Fungal Infections in Patients With Chronic Lymphocytic Leukemia Treated With Bruton Tyrosine Kinase Inhibitors: A Case-Control Propensity Score–Matched Analysis2024 · 5 citations
  2. 2The Immunologic Paradox of BTK Inhibitors in Chronic Lymphocytic Leukemia: Selectivity, Hypogammaglobulinemia, and Infection Risk2026
  3. 3Invasive Fungal Infections Following Bruton Tyrosine Kinase Inhibitor Treatment: A Systematic Review and Meta-analysis2026
  4. 4Real-world risk of bleeding events in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) treated with BTKi.2024
  5. 5Comparison of infections in patients with chronic lymphocytic leukemia (CLL) treated with BTKi versus venetoclax obinutuzumab in first line therapy2025